Retrospective, Multi-center Real-world Study of StimLabs Human Placental Membrane Tissue to Treat Hard-to-Heal Wounds
A Retrospective, Multi-center Real-world Study of StimLabs Human Placental Membrane Tissue Used for Treatment in Hard-to-Heal Wounds
1 other identifier
observational
50
1 country
3
Brief Summary
This is a retrospective, multi-center observational study to assess real-world outcomes of StimLabs human placental membrane tissue used in the treatment of hard-to-heal wounds, including chronic ulcers, diabetic foot ulcers (DFUs), and venous leg ulcers (VLUs). The collection of retrospective real-world data provides a broad range of experiences related to patient healthcare and treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2025
Shorter than P25 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2025
CompletedFirst Submitted
Initial submission to the registry
September 25, 2025
CompletedFirst Posted
Study publicly available on registry
October 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedOctober 10, 2025
September 1, 2025
2 months
September 25, 2025
October 8, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
The proportion of target ulcers achieving complete wound closure during the observational period
Determine the percent (%) of target ulcers achieving complete wound closure at 12 weeks.
1-12 weeks
Secondary Outcomes (3)
Percent area reduction
1-12 weeks
Time to closure for the target ulcer
1-12 weeks
Adverse events
1-12 weeks
Study Arms (1)
Retrospective Relese
Retrospective case review to include all subjects that received Relese between May 2023 to April 2025.
Eligibility Criteria
Consecutive subjects receiving Relese in a real-world setting
You may qualify if:
- Consecutive diabetic subjects that received a Relese product application during treatment between May 2023 and April 2025.
You may not qualify if:
- Subjects not receiving an initial Relese application during treatment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- StimLabslead
Study Sites (3)
Cypress Wound Care
Oklahoma City, Oklahoma, 73103, United States
Premier Foot & Ankle
Denison, Texas, 75020, United States
Premier Foot & Ankle
Frisco, Texas, 75033, United States
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 25, 2025
First Posted
October 10, 2025
Study Start
September 1, 2025
Primary Completion
November 1, 2025
Study Completion
December 1, 2025
Last Updated
October 10, 2025
Record last verified: 2025-09